Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 21, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic...
-
Mar 14, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will...
-
Mar 12, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the 16-week Liver Fat Imaging Study ("Liver Fat...
-
Mar 11, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown, Executive Vice President and Chief Financial Officer, will provide a corporate overview to...
-
Mar 6, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018. Fourth Quarter 2019 and Recent Corporate Highlights...
-
Feb 14, 2019
Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that the Phase 2 clinical study of LPCN 1144 in...
-
Jan 24, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration...
-
Jan 17, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced approximately eight-week top-line interim results from an ongoing sixteen-week Liver Fat Imaging study ("Liver Fat...
-
Jan 14, 2019
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") granted...
-
Dec 31, 2018
Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically...